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Abstract
Rationale Autism spectrum disorders (ASDs) affect 1 % of
children, having significant impact on health and social
outcomes. Psychotropic medication use by individuals with
ASD in the USA increased over time, and polypharmacy
occurred in >50 % of those prescribed. In the UK, no
psychotropic drugs are approved in ASDs, and little is
known about patterns of pharmacological treatment in the
ASD population and associated co-morbidities.
Methods We used The Health Improvement Network, a
nationally representative primary care database, to assess
the prevalence of ASD diagnoses, psychotropic drug
prescribing and neuropsychiatric co-morbidities of 0–
24 year olds between 1992 and 2008.
Results ASD prevalence increased 65-fold from 0.01 %
(1992) to 0.50 % (2008). Psychotropic drugs were pre-
scribed to 29 % (1,619/5,651) of the ASD cohort; the most
prescribed drugs were sleep medication (9.7 % of prescribed
patients), psychostimulants (7.9 %) and antipsychotics
(7.3 %). More patients were given psychostimulants and
sleep medications over time from 1.5–6.3 % and 2.2–
5.9 % respectively. Thirty-seven per cent of the cohort had
≥1 record of a neuropsychiatric co-morbidity, the most
common being developmental difficulties and learning dis-
abilities (12.6 %), behavioural, conduct and personality
disorders (11.1 %) and attention deficit hyperactivity disor-
der (7.5 %).
Conclusions British physicians are more conservative in
prescribing practice than American colleagues. However,
use of psychostimulants and antipsychotics is much higher
in those with ASD than in the general population.
Polypharmacy was seen in 34 % of prescribed patients in
2008. Additional studies examining use, efficacy, and long-
term safety of antipsychotics and psychostimulants in autis-
tic individuals are warranted.
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Introduction
Autistic spectrum disorders (ASDs) affect 1 in 88 children in
the USA. In the UK, the prevalence of ASD is about 1 % in
children (Baird et al. 2006; Baron-Cohen et al. 2009). ASDs
and associated co-morbid disorders significantly impact on
social outcomes, education and health (Bolton et al. 1998)
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due to the early onset of ASDs, their lifelong persistence and
associated pervasive impairments (Simonoff et al. 2008). The
annual societal cost in the UK of supporting children with
ASDs has been calculated as £2.7 billion, and these costs
amount to £25 billion per annum for adults, with estimated
lifetime costs of £1.7 million for those with intellectual dis-
ability and £0.8 million for those without (Knapp et al. 2009).
Furthermore, individuals with ASD have a very high preva-
lence of co-morbid mental health conditions including
attention-deficit hyperactivity disorder (ADHD), learning dis-
abilities, oppositional or conduct disorder, emotional disorders,
anxiety and other phobic disorders and chronic tic disorder
(Bradley and Bolton 2006; Green et al. 2005; Simonoff et al.
2008). Hence, the development and optimisation of interven-
tions (including behavioural treatment, educational approaches
and pharmacotherapy) to alleviate symptoms/impairments of
those with ASDs so as to improve the quality of life of in-
dividuals and their families is imperative.
Medication may be a helpful therapeutic intervention to
manage disabling behavioural and/or mental health symp-
toms in the autistic population; however, there are currently
no practice guidelines (Frazier et al. 2011). A review con-
cluded that although there is no standard medication for
treating ASD, people are prescribed a variety of psychotro-
pic medications (and there is scant reliable research evi-
dence supporting this practice in adolescents and adults)
(Broadstock et al. 2007). In fact, some have suggested that
individuals with ASDs experience decreased efficacy and
more adverse effects from psychiatric medications such as
behavioural toxicity with tricyclic antidepressants, and so-
cial withdrawal and irritability with methylphenidate
(Sanchez et al. 1996; Aman et al. 1997; Handen et al.
2000). This creates uncertainty about the appropriateness
of using existing pharmacological treatment(s) for co-
morbid conditions, such as ADHD (Frazier et al. 2011;
Aman et al. 2003), and has led to recent work on drug
effectiveness (Simonoff et al. 2012). Despite this uncertain-
ty, drug surveys and studies of health insurance claims
databases conducted in the USA have shown that over time
more psychotropic drugs (and in particular antipsychotics,
antidepressants and stimulants) are being prescribed to chil-
dren, young people and adults with ASD (Aman et al. 2005;
Oswald and Sonenklar 2007; Mandell et al. 2008; Esbensen
et al. 2009; Williams et al. 2012). For example, in North
Carolina, between 1992/1993 and 2001, psychotropic drug
use rose significantly from 30.5 % of children and adults
with autism to 45.2 %. Furthermore, antidepressant use
increased 3.5-fold - from 6.1 % in 1992/1993 to 21.4 % in
2001 (Aman et al. 2005). There is also increasing evidence
that the likelihood of an ASD person being prescribed
medication increases with age. For instance one study
reported that rates of psychotropic drug use rose from
56 % of 6–11 year olds to 73 % of 18–21 year olds
(Mandell et al. 2008). This is of importance because once
an individual has been prescribed a psychotropic medica-
tion, they are (a) 11 times more likely to remain on it than
for non-psychotropic drugs (Esbensen et al. 2009) and (b)
much more likely to be exposed to (potentially hazardous)
polypharmacy (e.g. some have reported that more than half
of children and youths with ASD who were prescribed
psychotropic medication experienced this (Logan et al.
2012; Frazier et al. 2011).
Although there is limited evidence to guide psychotropic
medication use in the ASD population, two drugs have
shown efficacy for the alleviation of behavioural symptoms
in children and adolescents with autistic disorder: risperi-
done (Research Units on Pediatric Psychopharmacology
Autism Network (RUPPAN) 2002; Shea et al. 2004) and
aripiprazole (Owen et al. 2009; Marcus et al. 2009). In 2006,
risperidone was approved by the Food and Drug
Administration (FDA) in the USA for the treatment of
irritability associated with autistic disorder in 5–16 year
olds; this includes aggression and deliberate self-
injuriousness. Aripiprazole was also approved by the FDA
in 2009 after demonstrating efficacy in the same indication
in 6–17 year olds (Owen et al. 2009; Marcus et al. 2009). An
application for UK approval was submitted but subsequent-
ly withdrawn by the licence holder of risperidone, Janssen-
Cilag, in 2006 after receiving an offer of conditional
approval—but limiting its indication to the symptomatic
treatment of severe aggression and violence in children with
autism (Morgan & Taylor 2007). Safety monitoring through
a treatment registry formed part of the conditions due to
concerns that risperidone could be misused as long-term
chemical control in children. In the UK, risperidone remains
unlicensed for use in children with autism, but it is approved
for the treatment of persistent aggression in conduct disorder
in children of sub-average intellectual functioning. The
reported side effects of antipsychotic drugs include signifi-
cant weight gain and other metabolic effects such as
hyperprolactinaemia and diabetes mellitus (Almandil and
Wong 2011; Almandil et al. 2013), and movement disorders
such as tardive dyskinesia, tremor and dystonia (Almandil
and Wong 2011; Fleischhaker et al. 2006; Robb et al. 2011);
life-threatening side effects such as rhabdomyolysis, neuro-
leptic malignant syndrome and seizures have also been
reported (Star et al. 2012; Rani et al. 2009, 2011).
However little is known about the long-term safety of anti-
psychotics, and polypharmacy with other drug classes, es-
pecially in the autistic population. This is a valid concern
because of the early diagnosis of ASDs and the lifetime
persistence of symptoms, which are increasingly managed
with psychotropic drugs (Esbensen et al. 2009).
Studies have identified substantial support needs for ASD
in terms of health, social care and educational services
(Knapp et al. 2009; Barrett et al. 2012), but to date, we have
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very little data in the UK about the prescribing of pharma-
cological treatment by young people with ASDs and asso-
ciated neuropsychiatric co-morbid disorders. Information
about prescribing practices and co-morbidities is necessary
for prioritising further research into the efficacy and short-
and long-term safety of psychotropic medications in this
particular patient population. Hence, we conducted an ob-
servational cohort study based on a primary care database to
investigate the pharmacological treatments used among a
cohort of children, adolescents and young adults diagnosed
with ASD.
Method
Study design
A descriptive cohort study was conducted using The Health
Improvement Network (THIN) database to investigate the
incidence and prevalence of ASD diagnoses, psychotropic
medication prescribing and neuropsychiatric related co-
morbidities of children, adolescents and young adults in
UK primary care.
Data source
THIN contains anonymised computerised information sys-
tematically recorded by general practitioners (GPs) in the
UK for patient management. The database provider collates
and organises this information in order for it to be used for
research. In the UK, almost all patient care is managed by
GPs in primary care, who act as gatekeepers of the UK
National Health Service. When required, GPs will refer
patients to hospital consultants or specialists in secondary
care for diagnosis and initiation of treatment, and GPs
usually continue to monitor their patients and issue pre-
scriptions. The diagnosis and management of ASDs and
the initiation of drug treatment for symptoms of ASDs (or
co-morbidities) is usually the responsibility of specialist
teams, and general practitioners manage patients in primary
care through shared care arrangements with these teams.
THIN covers approximately 5.7 % of the UK population
with 3.6 million active patients from 464 general practices
(Cegedim Strategic Data Medical Research UK 2009). The
demographic distribution of THIN is broadly representative
of that of the UK; therefore, analysis of the clinical and
prescribing data will provide information on trends that is
representative of national trends. This is particularly useful
in evaluating treatment rates, rates of specific diagnoses and
changes in these rates.
THIN is a rich source of clinical primary care data and
contains information on patient demographics, prescrip-
tions, diagnoses and referrals. Drugs are coded in the
database using MULTILEX® codes (First DataBank;
THIN). Diagnoses, symptoms and referrals are coded using
Read Clinical Terms, a comprehensive hierarchical system
(Chisholm 1990). The database has been previously used to
study trends in disease incidence and prescribing patterns in
paediatric and adult populations (McCarthy et al. 2012a,b;
Wijlaars et al. 2012). A previous study using a similar UK
primary care database (the former General Practice Research
Database; GPRD) has validated diagnoses of ASDs in GP
records by expert review and by a computerised diagnostic
algorithm of Diagnostic and Statistical Manual of Mental
Disorders (DSM)-IV symptoms ratings, showing they are
appropriate for the identification of ASD cases (Fombonne
et al. 2004). Practices who contribute to THIN and/or GPRD
use the same practice management software (Vision, In
Practice Systems Ltd), so data from both databases are
collected in a similar manner and structure; in fact a large
proportion (66 %, 327 of 495 practices in 2001–2008) of
practices contributing to THIN also contribute to GPRD
(Cai et al. 2012).
Study population
The study population comprised all individuals in THIN
who were children, adolescents and young adults aged
<25 years who had a record of diagnosis of ASD in the
study period between 1 January 1992 and 31 December
2009. The start date of each patient was defined as the latest
of the following: the date of the patient’s registration at the
general practice; the date that the general practice began
using the Vision software (a clinical management system);
and the date that the practice was deemed to meet a key
quality indicator known as the Acceptable Mortality
Reporting (Maguire et al. 2009). Patients were included if
they had an observation period of least 6 months available
from their start date and were registered with the general
practice during the study period.
Prevalence of ASD
Patient records dated within one year after a patient’s start
date (which may or may not be within the study period)
were screened to identify diagnoses of ASD. Any individual
with an ASD diagnosis within 1 year of the start date were
considered affected with ASD (i.e. prevalent) unless they
were aged <2 years at the time of the diagnosis. Autistic
disorder can be diagnosed in children as young as 2 years of
age, whereas those with Asperger disorder and pervasive
development disorder—not otherwise specified are fre-
quently not reliably diagnosed until 4–5 years of age
(Shattuck et al. 2009). Hence, patients with a record of
ASD at ages <2 years are likely to be incident with ASD.
Incident patients were defined as (1) those who have a first
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diagnosis of ASD following the first year screening period
and (2) those with an ASD diagnosis when aged<2 years
during the screening period. The index date for each patient
was defined as the date of the first recorded diagnosis of
ASD following the patient’s start date. The annual preva-
lence of ASD was calculated by counting all patients inci-
dent with ASD in a particular year and all prevalent patients
in active follow-up of that year divided by the total number
of individuals in the THIN mid-year population (i.e., those
who remained registered on the database on 1st July of that
calendar year). The annual incidence of ASD was calculated
by counting all patients incident with ASD in a particular
year divided by the total number of individuals in the THIN
mid-year population. Annual prevalence of ASD was calcu-
lated by age group defined as 0–5 year olds (young chil-
dren), 6–12 year olds (children), 13–17 year olds
(adolescents) and 18–24 year olds (young adults).
Drug prescribing
Nine categories of drugs were defined (by MLM, ES and
KG) as: stimulants (methylphenidate, dexamfetamine
and atomoxetine), antidepressants, antipsychotics,
antiepileptics/mood stabilisers, benzodiazepines, sleep med-
ication (including melatonin), clonidine, beta-blockers and
antiparkinsonism drugs that may be co-prescribed with an-
tipsychotics to counteract unwanted motor effects. The pre-
scriptions for the study drugs of each patient recorded on or
after their index date were identified, and the annual pro-
portions of the ASD cohort prescribed drug treatment were
calculated by drug category and by individual drug (with
95 % confidence intervals).
Co-morbidities
The clinical records of each patient recorded on or after their
index date were screened for neuropsychiatric co-morbidities.
Diagnostic codes (Read codes) were categorised into eleven
groups (by DGM, ES and MLM,): psychotic disorders
(including schizophrenia and delusions); behavioural,
conduct and personality disorders; mood disorders; anx-
iety and phobias (including obsessive–compulsive disor-
der); ADHD; suicidal behaviour and self-harm; anorexia
and bulimia; tic disorders; developmental difficulties and
learning disabilities; substance and alcohol misuse. The
proportions of the cohort with neuropsychiatric co-
morbidities were calculated.
Data management and analyses were performed using
Stata SE version 11.2 (StataCorp, College Station, TX,
USA).
The study protocol was granted approval by the Scientific
Review Committee of Cegedim Strategic Data (CSD)
Medical Research UK, the data providers of THIN.
Results
Characteristics of the ASD cohort
There were 5,651 patients aged under 25 years in the THIN
database with at least one diagnosis record of ASD during
the study period; 83.0 % were male (n=4,688). Table 1
provides details on the characteristics of the study cohort.
In 4,541 patients who became incident with ASD during the
study period, the mean age at first recorded diagnosis was
9.0 years (SD: 4.74 years); however, a bimodal distribution
of age was observed with peak frequencies of first diagnoses
recorded at 4 and 8 years of age. First diagnoses of ASD
were recorded at a later age in female than in male.
Prevalence/incidence of ASD diagnoses
Overall prevalence of ASD diagnoses during the study
period was 2.23 persons per 1,000 mid-year population
(MYP); the highest prevalence was seen in children with
3.87 children per 1000 MYP. In 2008, ASD prevalence for
young children was 2.06 per 1,000 MYP, 8.89 per
1,000 MYP in children, 6.64 per 1,000 MYP in adoles-
cents (13–17 years) and 2.44 per 1,000 MYP in young
adults (18–24 years).
Figure 1 shows the prevalence of ASD in the cohort over
the study period. The prevalence of ASD increased 64.6-
fold from 0.08 persons per 1,000 MYP in 1992 (95 % CI,
0.05–0.12) to 5.04 persons per 1,000 MYP in 2008 (95 %
CI, 4.89–5.19). The increase was greater in male (77.1-fold)
than in female (36.8-fold). The incidence of ASD also rose
in the same period by 23.7-fold from 0.03 persons per 1,000
MYP in 1992 (95 % CI, 0.01–0.05) to 0.67 persons per
1,000 MYP in 2008 (95 % CI, 0.61–0.72). The rise in
incidence was greater in female (32.9-fold) than male
(23.1-fold).
Drug prescribing
There was a total of 1,619 patients (28.7 %; 95 % CI, 27.3–
30.1 %) of the cohort who received 47,738 prescriptions for
the study drugs; proportionally, more female patients were
prescribed these drugs than male (Table 1). In 2008, 33.8 %
of those prescribed psychotropic medications (305 of 902
patients) were given prescriptions for two or more drugs.
The three most commonly prescribed drug groups overall
(and in male patients) were sleep medication [9.7 % overall
(95 % CI, 8.9–10.6 %), 10.0 % of male patients (95 % CI,
9.1–10.9 %)], stimulants [7.9 % overall (95 % CI, 7.2–
8.7 %), 8.7 % of male patients (95 % CI, 7.8–9.5 %)] and
antipsychotics [7.3 % overall (95 % CI, 6.7–8.1 %), 7.0 %
of male patients (95 % CI, 6.3–7.8 %)]; for female patients,
they were antiepileptics/mood stabilisers (11.0 %; 95 % CI,
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9.0–13.3 %), antidepressants (9.0 %; 95 % CI, 7.2–11.1 %),
and sleep medication (8.5 %; 95 % CI, 6.8–10.6 %).
Clonidine and beta-blockers were rarely prescribed; only
30 and 36 patients in the total cohort respectively were
prescribed these drugs. The five most commonly prescribed
drugs were methylphenidate (7.1 % of the ASD cohort;
95 % CI, 6.4–7.8 %), melatonin (5.7 %; 95 % CI, 5.1–
6.4 %), risperidone (5.6 %; 95 % CI, 5.0–6.3 %), diazepam
(3.2 %; 95 % CI, 2.8–3.7 %) and valproic acid [3.2 %; 95 %
CI, 2.8–3.7 %].
Stimulants accounted for 23.0 % (n=10,981) of all psy-
chotropic drug prescriptions issued to the cohort, and the
average number of prescriptions per patient was 24.6.
However, the drug group with the most prescriptions was
antiepileptics/mood stabilisers with 33.2 % of all prescrip-
tions (n=15,868); the mean number of prescriptions per
patient was 44.1 (Table 2).
The numbers of individuals with ASD diagnoses between
1992 and 1998 were relatively low (Fig. 1), which made
prescribing rates unstable. Consequently, Fig. 2 shows the
prescribing rates of the drug groups from 1999 to 2008 only.
The proportion of the cohort prescribed stimulants rose
by 4.7 % between 1999 (1.5 %; 95 % CI, 0.7–2.9 %) to
6.3 % (95 % CI, 5.6–7.0 %) in 2008 (Fig. 2a). Sleep
Table 1 Characteristics of the patient cohort with autistic spectrum disorder (ASD) diagnoses
Cohort characteristics All Male Female
Number of subjects aged 0–24 years (%) with at least one diagnosis of ASD 5,651 (100.0) 4,688 (83.0) 963 (17.0)
Mean age (SD) at first recorded diagnosis of ASD (years) 9.3 (5.05) 9.2 (4.92) 10.1 (5.60)
Median age (IQR) at first recorded diagnosis of ASD (years) 8.4 (7.24) 8.2 (6.92) 9.1 (8.64)
ASD diagnoses
Total number of ASD diagnoses 8,602 7,205 1,397
Mean number of ASD diagnoses per person (SD) 1.5 (1.25) 1.5 (1.27) 1.5 (1.10)
Median number of ASD diagnoses per person (IQR) 1.0 (1.00) 1.0 (1.00) 1.0 (1.00)
Prevalent/incident patients
Number of subjects prevalent with ASD (ASD diagnosis recorded
within one year of entry into study)
1,110 (19.6) 919 (19.6) 191 (19.8)
Number of subjects incident with ASD 4,541 (80.4) 3,769 (80.4) 772 (80.2)
Incident patients: mean age (SD) at first recorded diagnosis of ASD (years) 9.0 (4.74) 8.9 (4.61) 9.6 (5.29)
Incident patients: median age (IQR) at first recorded diagnosis of ASD (years) 8.1 (6.72) 8.0 (6.44) 8.5 (8.08)
Incident patients: mean number of ASD diagnoses per person (SD) 1.5 (1.33) 1.5 (1.34) 1.4 (1.28)
Incident patients: median number of ASD diagnoses per person (IQR) 1.0 (1.00) 1.0 (1.00) 1.0 (1.00)
Prescribing
Total number of prescriptions prescribed post-index date 158,285 122,587 35,698
Number of study drug prescriptions issued at any time post-index date 47,738 36,983 10,755
Total number of patients (%) prescribed at least one prescription for a study drug 1,619 (28.6) 1,312 (28.0) 307 (31.9)
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medications also were prescribed to 3.7 % more young
people during the same period [2.2 % (95 % CI, 1.2–
3.8 %) in 1999 to 5.9 % (95 % CI, 5.2–6.6 %) in 2008].
The prescribing of benzodiazepines, antipsychotics, and
antiparkinsonism drugs remained stable (Figs. 2a, b), and a
slight downward trend in antidepressant use was seen
(Fig. 2c). There was a 1.8 % decline in the proportion of
patients prescribed antiepileptic drugs between 1999 and
2008, from 6.1 % (95 % CI, 4.3–8.4 %) to 4.3 % (95 %
CI, 3.7–4.9 %; Fig. 2c).
Psychiatric co-morbidities
There were 2,062 patients (36.5 % of cohort; 95 % CI, 34.9–
38.1 %) who had at least one record of a neuropsychiatric co-
morbidity on or after their first recorded diagnosis of ASD on
the database. The most common neuropsychiatric co-
morbidities were developmental difficulties and learning disabil-
ities (12.6 % of the cohort; 95 % CI, 11.7–13.6 %), behavioural,
conduct and personality disorders (11.1 %; 95 % CI, 10.3–
12.0 %), ADHD (7.5 %; 95 % CI, 6.8–8.2 %), and epilepsy
(5.0%; 95%CI, 4.4–5.6%; Table 3). Of those with anADHD
diagnosis, 62.0 % (n=261) were prescribed a psychostimulant
during the study period, and 21.4 % (n=90) received at least
one prescription for a sleep medication. Furthermore, 41.5 %
(185/446) of those given at least one psychostimulant pre-
scription had no co-morbidity of ADHD recorded during the
period. Almost three quarters of patients (n=210) with epilep-
sy recorded were prescribed an antiepileptic drug.
Discussion
To our knowledge, this is the first naturalistic study of
psychotropic drug prescribing and neuropsychiatric co-
morbidities in a large nationally representative cohort of
ASD patients in UK primary care. The database has provid-
ed rich longitudinal data to enable us to characterise the
autistic population and the prescribing practices of GPs
undertaking their clinical care (usually by shared care ar-
rangements with secondary care physicians).
We found the incidence and prevalence of ASD have
substantially increased 23.7- and 64.6-fold, respectively,
over the period between 1992 and 2008. These increases
may be due to improved recognition and diagnosis of ASD,
broadened diagnostic criteria and increased awareness and
acceptance of ASD by healthcare professionals and parents
(Baird et al. 2006; Baron-Cohen et al. 2009; Simonoff
2012). The 2008 prevalence of ASD diagnoses in 6–12 year
olds of our cohort (0.89 %; 95 % CI, 0.85–0.93 %) is
comparable to that reported by Baird et al. (2006) (1.16 %;
95 % CI, 0.90–1.42 %) from their Special Needs and
Autism Project sample (SNAP) and the estimate of 1.57 %Ta
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(95 % CI, 0.9–2.46 %) in a Cambridgeshire school-based
population (Baron-Cohen et al. 2009).
There was more conservative use of psychotropic drugs
by British GPs (usually initiated by specialist physicians)
compared with the practices of their American colleagues.
Only 29 % of our cohort (26 % aged 0–21 years) received
psychotropic drug prescriptions in UK primary care. In con-
trast, Mandell et al. (2008) found 56 % of Medicaid-enrolled
youths with ASDs aged 0–21 years received at least one
psychotropic drug in 2001; likewise, in 2002, 57 % of under
0
1
2
3
4
5
6
7
8
Pe
rc
e
n
ta
ge
 
o
f A
SD
 
co
ho
rt
Stimulants
Sleep medication
Benzodiazepines
0
1
2
3
4
5
6
7
Pe
rc
e
n
ta
ge
 
o
f A
SD
 
co
ho
rt
Antipsychotics Antiparkinsonism drugs
0
1
2
3
4
5
6
7
8
9
Pe
rc
e
n
ta
ge
 
o
f A
SD
 
co
ho
rt
Antidepressants Antiepileptics & mood stabilisers
a
b
c
Fig. 2 Proportion of cohort
with autistic spectrum disorder
(ASD) prescribed: a stimulants,
sleep medication
or benzodiazepines;
b antipsychotic
or antiparkinsonism drugs;
c antidepressants
or antiepileptics and mood
stabilisers (1999–2008)
Psychopharmacology (2014) 231:1011–1021 1017
21s enrolled to another US claims database (MarketScan®)
were prescribed psychotropic drugs (Oswald and Sonenklar
2007).
Psychotropic drug prescribing practices will be strongly
influenced by co-morbidities associated with ASDs, which
may explain the large proportion of those prescribed psy-
chotropic drugs who were given more than one psychotropic
drug (34 % of prescribed patients in 2008). A third of our
cohort had at least one neuropsychiatric co-morbidity
recorded in their primary care records following ASD diag-
nosis, the most common being developmental difficulties
and learning disabilities, behavioural, conduct and person-
ality disorders and ADHD. Simonoff et al. (2008) found in
their SNAP cohort that 28.2 % were co-morbid with ADHD,
30.0 % had oppositional or conduct disorder and 41.9 % had
anxiety or phobias; our cohort had much lower proportions
of these co-morbidities. It is possible that there was under-
recording as specialist physicians may find it difficult to
diagnose co-morbid psychiatric disorders due to communi-
cation impairment or cognitive problems in individuals
(Leyfer et al. 2006). Alternatively, there may be nosological
conventions, which exclude the diagnosis of certain symp-
toms as co-morbid psychiatric disorders, for example, symp-
toms of hyperactivity and impulsiveness in autistic people
may not be reported as ADHD (RUPPAN 2005; White et al.
2009). New diagnostic guidelines in DSM-5 and almost
certainly International Classification of Diseases 11th revi-
sion will remove the exclusion of making a diagnosis of
ADHD in the context of ASD, which has been present.
Therefore, a large proportion of stimulant prescribing in
our study is likely to be for the treatment of co-morbid
ADHD or symptoms of hyperactivity (Simonoff et al.
2008; Frazier et al. 2011), even though two fifths of
stimulant-prescribed patients did not have an ADHD diag-
nosis recorded during the study period.
We found that individuals with ASD are much more
likely to be prescribed psychostimulants in comparison with
the UK general population. For example, McCarthy et al.
(2012a) reported that 0.92 and 0.74 % of children aged
6–12 years and 13–17 years, respectively, in THIN were
prescribed a stimulant drug in 2008. However, 6.60 %
(of 6–12 years olds) and 8.79 % (13–17 years) of our
cohort received at least one prescription for methylphe-
nidate, dexamfetamine or atomoxetine in the same year.
Thus, compared with a child in the general population,
a child with ASD is seven times more likely to be
prescribed a psychostimulant. For autistic adolescents,
psychostimulant prescribing is almost 12 times higher
than that of the general population.
The increase in prescribing of stimulants over time may
reflect the increasing recognition of co-morbid ADHD (and
its persistence) in young people with ASDs. In addition,
secondary care physicians may be more willing to initiate
(and general practitioners more willing to prescribe) meth-
ylphenidate following evidence that it is effective in some
autistic young people with ADHD (RUPPAN 2005).
Two thirds of the autistic population are reported as
having moderate sleep disturbances (Souders et al. 2009);
however, <10 % of our cohort received sleep medications
(<5 % were prescribed benzodiazepines, some of which may
be used to alleviate sleep problems); it is likely that UK GPs
only consider to prescribe pharmacological treatments to
patients with severe sleeping disorders. It is interesting to
note the rising trend of sleep medication prescribing. The
trend may be due to increased diagnosis of co-morbid
ADHD and/or the use of sleeping medications to counteract
the effects of stimulants on sleep.
Prescribing for antipsychotics and antidepressants in the
cohort was relatively stable between 1999 and 2008, at the
overall prescribing rates of 4.1 % (95 % CI, 3.85–4.37 %)
Table 3 Neuropsychiatric co-
morbidities of the cohort with
autistic spectrum disorder
Neuropsychiatric co-morbidities All Male Female
Attention deficit hyperactivity disorder 421 (7.5) 378 (8.1) 43 (4.5)
Anorexia and bulimia 47 (0.8) 30 (0.6) 17 (1.8)
Anxiety and phobias (including obsessive
compulsive disorder)
251 (4.4) 192 (4.1) 59 (6.1)
Behavioural, conduct and personality disorders 628 (11.1) 505 (10.8) 123 (12.8)
Mood disorders 189 (3.3) 134 (2.9) 55 (5.7)
Epilepsy 283 (5.0) 209 (4.5) 74 (7.7)
Developmental difficulties and learning disabilities 713 (12.6) 562 (12.0) 151 (15.7)
Psychotic disorders (including schizophrenia and delusions) 37 (0.7) 29 (0.6) 8 (0.8)
Substance and alcohol misuse 18 (0.3) 13 (0.3) 5 (0.5)
Suicidal behaviour and self-harm 63 (1.1) 45 (1.0) 18 (1.9)
Tic disorders 64 (1.1) 60 (1.3) 4 (0.4)
Unclassified neuropsychiatric disorders 287 (5.1) 227 (4.8) 60 (6.2)
Any neuropsychiatric co-morbidity 2,062 (36.5) 1,669 (35.6) 393 (40.8)
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and 3.3 % (95 % CI, 3.03–3.49 %) respectively. This differs
to reported increases in antidepressant and antipsychotic use
in the American autistic population. Two drug surveys
conducted in North Carolina in 1992/1993 and 2001 re-
vealed a significant 3.5-fold increase in the proportion of
children and adults with autism prescribed antidepressants
(Aman et al. 2005). Williams et al. (2012) found that use of
antipsychotics was high (34 % in 2008 compared to 7 % of
our cohort) in their study of Kentucky-based children with
autism. This was attributed to the greater use of atypical
antipsychotics following the licensing of risperidone in the
USA for the treatment of irritability associated with autistic
disorder (Williams et al. 2012). Although risperidone re-
mains unlicensed in the UK for this indication, we still
found a fifth of the cohort who were prescribed psychotro-
pic drugs were given risperidone. While the ratio of the
cohort prescribed antipsychotics has remained relatively
stable between 1999 and 2008, a high proportion of children
and teenagers with ASD are prescribed antipsychotics in
comparison with the general British population. In 2005,
the prevalence of antipsychotic prescribing in 0–18 year
olds is reported to be 0.08 % (Rani et al. 2008) compared
to 2.98 % of the same age group in our cohort (a 38.7-fold
increased risk).
Antiparkinsonism drugs were prescribed to a very small
proportion of patients (0.8 % of ASD cohort, n=43) prob-
ably to mitigate extrapyramidal symptoms of antipsychotics
as has been reported elsewhere (Esbensen et al. 2009).
There may be some underestimation of prescribing as
some patients may be treated in specialist centres and
THIN does not systematically record prescriptions generat-
ed in non-primary care healthcare settings (some informa-
tion on drug treatment may be recorded in discharge
summaries and hospital letters). Furthermore, some GPs
may not participate in shared care prescribing arrangements,
especially of psychotropic drugs in off-label use and con-
trolled drugs such as the psychostimulants—methylphenidate
and dexamfetamine. The database does not record treatment
compliance or dispensing of prescriptions. There may be
underestimation of neuropsychiatric co-morbidities due to
the censoring of patient records, or incomplete transcription
of clinical details from correspondence with specialist teams.
Lastly, prescriptions are not directly linked to diagnoses in
THIN, so we cannot definitely identify indications of use.
Further assessment of the efficacy and short- and long-
term safety of psychotropic drugs for the treatment of
behavioural problems in this population is urgently
required as only two drugs so far, risperidone and
aripiprazole, have shown efficacy (RUPPAN 2002; Shea
et al. 2004; Owen et al. 2009; Marcus et al. 2009). More
recently, optimal dosing of methylphenidate was shown
to be effective in reducing ADHD symptoms in about
40 % of children with intellectual disability (including
those with ASDs), and the adverse effects profile was
similar to that seen in typically developing children
(Simonoff et al. 2012). Safety is an important consider-
ation across all ages due to the lifetime persistence of
symptoms and impairment, polypharmacy of psychotropic
medications and the difficulties that some individuals
may have in communicating about adverse effects.
More information on psychotropic drug use (and the
appropriateness of prescribing for co-morbidities) in the
ASD population across Europe would be beneficial to
focus European drug research activities and to inform
clinical practice. Furthermore, there is a need to prioritise
research of the most commonly prescribed drugs in the
autistic population: the antipsychotics (in particular ris-
peridone safety), the psychostimulants (especially efficacy
and safety in those co-morbid with ADHD) and sleep
medications.
Conclusions
The increase in prevalence of ASD diagnoses recorded
in UK primary care between 1992 and 2008 may be
due to improved recognition of ASDs, widening diag-
nostic criteria and more awareness and acceptance of
the conditions. However, there is under-reporting of
neuropsychiatric co-morbidities in the British autistic
population following diagnosis with ASDs, possibly
due to diagnostic exclusion or communication difficul-
ties in patients. Less than a third of individuals with
ASD receive at least one psychotropic drug prescription,
which are mostly for stimulants, antiepileptic drugs and
mood stabilisers and antipsychotics. Of those who are
prescribed psychotropic medication, a fifth is treated
with risperidone, and at least a third received more than
one drug. Hence, further research into the appropriate
use, efficacy and long-term safety of antipsychotics and
stimulants in the autistic population is warranted to
support clinical practice for optimal and safe treatment
of ASDs and their co-morbidities.
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